Immunomics technology provides custom solutions for protein target and epitope validation, antibody cross-reactivity analysis, and biomarker discovery.
With the rise in novel infectious agents leading to disease pandemics, a new era of vaccine discovery and development has now begun. In response, the field of Immunomics has become critical to designing robust modern vaccines tailored to both the genetic make-up of the human population and of the pathogen.
By incorporating inciteful high-quality data from proteomics, immunomics is geared to deliver an insight into immune function – e.g. antibody reactivity profiles, optimised immune response, and the selection and mapping of targets.
We can offer innovative high throughput technologies using protein and peptide microarrays, multiplex protein analyses, and ELISA (enzyme-linked immunosorbent assay), as analysis and assay development services. The use of high-density protein and peptide array technologies provides custom solutions for protein target and epitope validation, antibody cross-reactivity analysis, or biomarker discovery (e.g. by profiling of antibody-reactivity from patients and controls – using 10µl of serum a/o plasma, etc.).
